Processing...
Clinical Trials for Sarcoma
Search
Search
There are 170 active trials for advanced/metastatic sarcoma.
Click on a trial to see more information.
170 trials meet filter criteria.
Sort by:
TrialFetch AI summary: Enrolls adults with metastatic or locally advanced unresectable solid tumors (ECOG ≤2; measurable/evaluable by RECIST) with biologic rationale for RBM39 degradation; adolescents ≥16 may enroll for Ewing sarcoma or other supported malignancies, and stable treated brain metastases are allowed. Patients receive oral ST-01156, a small-molecule molecular glue RBM39 degrader (RNA-binding/splicing factor), dosed once daily on a 5-days-on/2-days-off schedule in 28-day cycles with dose escalation to define MTD/RP2D and assess early antitumor activity.
ClinicalTrials.gov ID: NCT07197554
TrialFetch AI summary: For adults (≥18) with relapsed/refractory, measurable soft tissue sarcoma after ≥1 prior systemic regimen (ECOG 0–1) whose tumors are FAP-PET–positive, this study treats with IV [Ac-225]RTX-2358, a fibroblast activation protein (FAP)–targeted actinium-225 alpha-emitting radiopharmaceutical delivering high–linear energy transfer cytotoxic radiation to the tumor microenvironment, dosed every 8 weeks for 4 cycles (up to 6 if benefiting). Patients also receive the investigational FAP-targeted PET imaging agent [Cu-64]LNTH-1363S for selection/imaging and dosimetry assessments.
ClinicalTrials.gov ID: NCT07156565
TrialFetch AI summary: Eligible patients are children, adolescents, and young adults (age 1 to <24 years; >10 kg) with relapsed/refractory rhabdomyosarcoma, Ewing sarcoma, neuroblastoma, or Wilms tumor with measurable/evaluable disease after standard therapies and no known CNS involvement. After fludarabine/cyclophosphamide lymphodepletion, participants receive a single infusion of an autologous 1:1 cellular product combining B7-H3–targeted CAR T cells with PRAME antigen–specific T cells engineered with a dominant-negative TGF-β receptor II (dTβRII) to resist TGF-β–mediated immunosuppression.
ClinicalTrials.gov ID: NCT07172958
TrialFetch AI summary: Adults with ECOG 0–1 and locally advanced unresectable or metastatic sarcoma (≤2 prior metastatic systemic lines) or selected epithelial solid tumors (≤3 prior lines) with RECIST-measurable disease and required pretreatment biopsy/archival tissue are treated with ZL-6201 monotherapy in 21-day cycles. ZL-6201 is a first-in-human LRRC15-targeting antibody–drug conjugate delivering an internalized camptothecin-derivative (topoisomerase I inhibitor) payload via a protease-cleavable linker.
ClinicalTrials.gov ID: NCT07374848
TrialFetch AI summary: Adults with locally advanced or metastatic solid tumors refractory to standard therapy or without proven effective options receive KIVU-107, an investigational PTK7-directed antibody-drug conjugate carrying an exatecan/topoisomerase I inhibitor payload. The study includes dose escalation followed by expansion at the recommended dose, with eligibility requiring measurable disease, ECOG 0–1, and adequate organ function.
ClinicalTrials.gov ID: NCT07229313
TrialFetch AI summary: Open-label dose-escalation study of oral KST-6051, an investigational pan-KRAS inhibitor targeting both active and inactive KRAS conformations, in adults with locally advanced unresectable or metastatic KRAS-mutant solid tumors including NSCLC, pancreatic, colorectal, and other cancers. Patients must have progressed after or been intolerant of standard therapy, have ECOG 0-1 and measurable disease, with no prior/current RAS/KRAS inhibitor therapy or CNS metastases.
ClinicalTrials.gov ID: NCT07458347
TrialFetch AI summary: This trial involves adult patients with refractory solid tumors unresponsive or declining standard treatments, evaluating the PCNA inhibitor AOH1996, which targets a cancer-specific variant to impair DNA replication and repair, dosed orally twice daily in a 28-day cycle.
ClinicalTrials.gov ID: NCT05227326
TrialFetch AI summary: This trial enrolls adults with advanced solid tumors or lymphoma that are refractory to standard therapies, whose tumors overexpress TrkA or harbor an NTRK1 gene fusion, to receive oral VMD-928, a highly selective irreversible TrkA inhibitor that acts via allosteric dimerization and inactivation of the target. Key exclusions include significant comorbidities and impaired drug absorption.
ClinicalTrials.gov ID: NCT03556228
TrialFetch AI summary: Enrolls adults with relapsed/refractory or treatment-ineligible advanced/metastatic solid tumors (ECOG 0–1) who have at least two injectable lesions, with emphasis on cutaneous and head/neck cancers (e.g., cSCC, BCC, melanoma, Merkel cell carcinoma, HNSCC) including anti–PD-1–refractory cohorts. Patients receive intratumoral MQ710/MQ719, a non-replicating modified vaccinia Ankara virotherapy (E5R-deleted to enhance cGAS/STING signaling and engineered to express Flt3L and OX40L), given in escalating multi-dose schedules alone or combined with systemic pembrolizumab (PD-1 inhibitor).
ClinicalTrials.gov ID: NCT05859074
TrialFetch AI summary: Adults with ECOG 0–2 melanoma (stage IIB–IV with progression on or within 6 months after adjuvant anti–PD-1, including select rare subtypes with metastatic immunotherapy failure) or unresectable stage II/III–IV soft tissue sarcoma with accessible measurable disease and early resistance/need to continue anti–PD-1 therapy are enrolled, requiring surgically obtainable tumor for vaccine manufacture. Patients receive an individualized autologous total tumor mRNA vaccine formulated in DOTAP lipid particles (IV 3-dose series) intended to enhance antigen presentation/innate activation and re-sensitize to checkpoint blockade, followed by continuation/resumption of anti–PD-1 per protocol.
ClinicalTrials.gov ID: NCT05264974